抄録
We studied the clinical effect and safety of AA-673 (25mg) tablets in 84 patients with perennial allergic rhinitis at 4 institutions. The patients received a 25mg tablet of AA-673 three times daily for at least 4 weeks.
The final global improvement rating showed “moderate to marked improvement”in 42% of the patients, and “slight to marked improvement”in 76%. The global improvement rate rose from two weeks to four weeks after the start of the administration. Subjective improvement of sneezing attacks, nasal discharge and nasal obstructaon was reported by 50%, 58% and 51% of the patients, respectively.
Side effects, observed in 7 patients (8.3%), were all mild and transient.
We consider AA-673 (25mg) tablets to be effective for the treatment of peren-nial allergic rhinitis.
